Elevation of Systemic Oxygen Delivery in the Treatment of Critically Ill Patients
Authors:
- Andrew C. TimminsATAndrew C. Timmins
- Ernest YauEYErnest Yau
- Mark PalazzoMPMark Palazzo
- Charles J. HindsCHCharles J. Hinds
- David WatsonDWDavid Watson
- 16 June 1994
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 330 (24) , 1717-1722
Abstract
Elevation of systemic oxygen delivery and consumption has been associated with an improved outcome in critically ill patients. We conducted a randomized trial to determine whether boosting oxygen delivery by infusing the inotropic agent dobutamine would improve the outcome in a diverse group of such patients. On the basis of previously published recommendations, we established the following goals: a cardiac index above 4.5 liters per minute per square meter of body-surface area, oxygen delivery above 600 ml per minute per square meter, and oxygen consumption above 170 ml per minute per square meter. If these goals were not achieved with volume expansion alone, patients were randomly assigned to a treatment or control group. The treatment group received intravenous dobutamine (5 to 200 μg per kilogram of body weight per minute) until all three goals had been achieved. Dobutamine was administered to the control group only if the cardiac index was below 2.8 liters per minute per square meter. A total of 109 patients were studied. In nine patients the therapeutic goals were achieved with volume expansion alone; all nine patients survived to leave the hospital. Fifty patients were randomly assigned to the treatment group, and 50 to the control group. During treatment, there were no differences between the two groups in mean arterial pressure or oxygen consumption, despite a significantly higher cardiac index and level of oxygen delivery in the treatment group (P<0.05). Although the predicted risk of death during hospitalization was 34 percent for both groups, the in-hospital mortality was lower in the control group (34 percent) than in the treatment group (54 percent) (P = 0.04; 95 percent confidence interval, 0.9 to 39.1 percent). The use of dobutamine to boost the cardiac index and systemic oxygen delivery failed to improve the outcome in this heterogeneous group of critically ill patients. Contrary to what might have been expected, our results suggest that in some cases aggressive efforts to increase oxygen consumption may have been detrimental. .Keywords
This publication has 19 references indexed in Scilit:
- A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients1993
- Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patientsCritical Care Medicine, 1993
- Oxygen Delivery and Uptake in Septic Patients1993
- When to stop a clinical trial.BMJ, 1992
- Septic shock: a goal‐directed therapy using volume loading, dobutamine and/or norepinephrineActa Anaesthesiologica Scandinavica, 1990
- Use of survivorsʼ cardiorespiratory values as therapeutic goals in septic shockCritical Care Medicine, 1989
- Tissue oxygen debt as a determinant of lethal and nonlethal postoperative organ failureCritical Care Medicine, 1988
- A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 1987
- APACHE IICritical Care Medicine, 1985
- Hemodynamic and oxygen transport patterns in surviving and nonsurviving postoperative patientsCritical Care Medicine, 1985